Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 19 May 2022

 
 
 
   

International Clinical Trials Day

 

Enhancing public health through responsible Clinical Trials Data Sharing
19 May 2022

International Clinical Trials Day: EFPIA’s commitment to advancing data transparency in a changing world Read more

Digital Health Technologies in Drug Development
19 May 2022

Accelerating the momentum in Europe Read more

Complex Clinical Trials – A decade of innovation in clinical research
19 May 2022

From a Drug centric to a Patient centric approach Read more

 
 
 
   

#WeWontRest until we beat cancer

 

Bladder Cancer Awareness Month: an opportunity for collaborative action to address pressing...
17 May 2022

As our understanding of predictive biomarkers grows, we have the potential to change what a cancer diagnosis means for... Read more

Bladder cancer: the Cinderella of cancers
18 May 2022 - Alan McDougall

Prioritising bladder cancer in EU health policy and research frameworks can help reduce disease burden and support progress... Read more

Revising the EU Council Recommendation on cancer screening: an opportunity to step up the fight...
16 May 2022 - Catherine Owen

We are committed to working with all stakeholders to achieve tangible progress for patients with cancer, keeping the... Read more

 
 
 
   

Events

 

Importance of Diversity & Equal Opportunities in a Healthy R&D Environment
02 June 2022 (June 2, 14:00-15:30 CET)

Workforce and Organizational Culture Read more

Future Clinical Trials conference – from tomorrow to 2030 – Why choose the Nordics?
07 June 2022 (in Helsinki or virtually)

The event will take place in Team Finland House (Porkkalankatu 1, Helsinki). It is also possible to follow the event... Read more

 
 
 
   

We published

Cardiovascular disease (CVD) is Europe’s number one killer, taking the lives of 5,000 Europeans every day. A new report by PwC, commissioned by the EFPIA CVD Network, set out to understand the impact of the pandemic on the 60 million CVD patients living in Europe. More than that, the report – Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare – offers a series of concrete recommendations designed to better position European health systems to cope with future crises.


 
 
 
 
   

What we are reading

 

France is making innovative drugs more accessible, but it can still do better
On 16 May 2022 (Le Monde)

It takes an average of 497 days in France for a new treatment approved by the European Medicines Agency to actually... Read more

Finance, culture, talent: why Europe struggles to commercialise its biotech expertise
On 21 March 2022 (Financial Times)

The continent is eager to capitalise on BioNTech’s Covid-19 success — but matching the scale of US hubs will be hard... Read more